Cabaletta Bio Inc. announced the appointment of David J. Chang, M.D., M.P.H., as Chief Medical Officer. Dr. Chang joins Cabaletta as the Chief Medical Officer with more than 25 years of clinical development experience in autoimmunity, neuroscience, and inflammatory diseases at both biopharmaceutical companies and in academia. He most recently served as the Senior Vice President and Head of Inflammation, Autoimmunity and Neuroscience, Global Medicines Development, at AstraZeneca, and previously he was Vice President and Head of Immuno-Inflammation, Clinical Development, at GlaxoSmithKline.